Specimen quality evaluation in canadian biobanks participating in the COEUR repository

Biopreservation and Biobanking

Volumn 11, Issue 2, 2013, Pages 83-93

  Le Page, Cécile ^a,b   Köbel, Martin ^c   De Ladurantaye, Manon ^a,b   Rahimi, Kurosh ^a   Madore, Jason ^a   Babinszky, Sindy ^d   Bachvarov, Dimcho R ^e,f   Bachvarova, Magdalena ^f   Beauchamp, Marie Claude ^g   Cass, Carol E ^h   Chadwick, Dianne ⁱ   Colleen, Crane ^j   Damaraju, Sambasivarao ^h   Dufour, Jennifer ^h   Gotlieb, Walter H ^g,k   Kalloger, Steve E ^l   Portelance, Lise ^a   McAlpine, Jessica N ^d,l,q   Matte, Isabelle ^m   Piché, Alain ^m   Shaw, Patricia ^i,n   Vanderhyden, Barbara C ^j   Watson, Peter H ^d,l,o   Huntsman, David G ^d,l,p   Provencher, Diane M ^a,b,q   Mes Masson, Anne Marie ^b,q   more..

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Institut du Cancer de Montreal   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f UNIVERSITÉ LAVAL   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

^j OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^k MCGILL UNIVERSITY   (Canada)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m UNIVERSITÉ DE SHERBROOKE   (Canada)

ⁿ PRINCESS MARGARET HOSPITAL   (Canada)

^o UNIVERSITY OF VICTORIA   (Canada)

^p VANCOUVER GENERAL HOSPITAL   (Canada)

^q UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 7; DNA; KI 67 ANTIGEN; PARAFFIN; PROTEIN P53; UVOMORULIN; WT1 PROTEIN; RNA;

ADULT; AGED; ANALYZER; ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; RNA EXTRACTION; STANDARD; TISSUE MICROARRAY; CANADA; HEALTH CARE FACILITY; LABORATORY DIAGNOSIS; METABOLISM; MIDDLE AGED; STAINING; STANDARDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL SPECIMEN BANKS; CANADA; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; RNA, NEOPLASM; SPECIMEN HANDLING; STAINING AND LABELING; TISSUE ARRAY ANALYSIS;

EID: 84876936830     PISSN: 19475535     EISSN: 19475543     Source Type: Journal    
DOI: 10.1089/bio.2012.0044     Document Type: Article

References (28)

1. Michener CM, Belinson JL. Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease. Oncology (Williston Park) 2005;19:1277-1285; discussion 1285, 1288, 1293.
2. Opitz L, Salinas-Riester G, Grade M, et al. Impact of RNA degradation on gene expression profiling. BMC Med Genomics 2010;3:36.
3. Bray SE, Paulin FE, Fong SC, et al. Gene expression in colorectal neoplasia: Modifications induced by tissue ischaemic time and tissue handling protocol. Histopathology 2010;56:240-250.
4. Barnes RO, Parisien M, Murphy LC, Watson PH. Influence of evolution in tumor biobanking on the interpretation of translational research. Cancer Epidemiol Biomarkers Prev 2008;17: 3344-3350.
5. De Cecco L, Musella V, Veneroni S, et al. Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer 2009;9:409.
6. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med 2008;5:e232.
7. Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 2003;91:504-512. (Pubitemid 38388142)
8. Dev H, Rickman D, Sooriakumaran P, et al. Biobanking after robotic-assisted radical prostatectomy: A quality assessment of providing prostate tissue for RNA studies. J Transl Med 2011;9:121.
9. Rudloff U, Bhanot U, Gerald W, et al. Biobanking of human pancreas cancer tissue: Impact of ex-vivo procurement times on RNA quality. Ann Surg Oncol 2010;17:2229-2236.
10. Dumur CI, Sana S, Ladd AC, et al. Assessing the impact of tissue devitalization time on genome-wide gene expression analysis in ovarian tumor samples. Diagn Mol Pathol 2008;17:200-206.
11. Jochumsen KM, Tan Q, Dahlgaard J, Kruse TA, Mogensen O. RNA quality and gene expression analysis of ovarian tumor tissue undergoing repeated thaw-freezing. Exp Mol Pathol 2007; 82:95-102. (Pubitemid 46038267)
12. Hecht JL, Kotsopoulos J, Gates MA, Hankinson SE, Tworoger SS. Validation of tissue microarray technology in ovarian cancer: Results from the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev 2008;17:3043-3050.
13. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004;23:200-205. (Pubitemid 38857108)
14. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 2008;61:152-163. (Pubitemid 351218874)
15. Kobel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: A transcanadian study. Am J Surg Pathol 2010;34:984-993.
16. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008;39:1239-1251.
17. Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 2007;31:1168-1174. (Pubitemid 47207118)
18. Han G, Gilks CB, Leung S, et al. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: An interobserver correlative and immunohistochemical study of 32 cases. Am J Surg Pathol 2008;32:955-964.
19. Kalloger SE, Kobel M, Leung S, et al. Calculator for ovarian carcinoma subtype prediction. Mod Pathol 2011;24:512-521.
20. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009;33:14-21.
21. Madore J, Ren F, Filali-Mouhim A, et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol 2010;220: 392-400.
22. McCluggage WG, Soslow RA, Gilks CB. Patterns of p53 immunoreactivity in endometrial carcinomas: 'All or nothing' staining is of importance. Histopathology 2011;59:786-788.
23. Yamamoto S, Tsuda H, Kita T, et al. Clinicopathological significance of WT1 expression in ovarian cancer: A possible accelerator of tumor progression in serous adenocarcinoma. Virchows Arch 2007;451:27-35.
24. Khoury T. Delay to formalin fixation alters morphology and immunohistochemistry for breast carcinoma. Appl Immunohistochem Mol Morphol 2012;20:531-542.
25. Darai E, Scoazec JY, Walker-Combrouze F, et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: A clinicopathologic study of 60 cases. Hum Pathol 1997; 28:922-928. (Pubitemid 27355552)
26. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol 2004;15: 1535-1542. (Pubitemid 39409745)
27. Voutilainen KA, Anttila MA, Sillanpaa SM, et al. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol 2006;59:460-467.
28. Shim HS, Yoon BS, Cho NH. Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Hum Pathol 2009;40:693-698.